Silver Book Fact

Cytokines in urine are associated with age-related macular degeneration (AMD) and could be developed as a biomarker and provide a practical tool for early detection

Guymer, Robyn H. Lingwui W. Tao, Jonathan K. Goh, Danny Liew, Olga Ischenko, Liubov D. Robman, KhinZaw Aung, Tania Cipriani, Melinda Cain, Andrea J. Richardson, Paul N. Baird, and Robyn Langham. Identification of Urine Biomarkers for AMD. Invest Opthalmol Vis Sci. 2011; 52(7): 4639-4644

Reference

Title
Identification of Urine Biomarkers for AMD
Publication
Invest Opthalmol Vis Sci
Publication Date
2011
Authors
Guymer, Robyn H. Lingwui W. Tao, Jonathan K. Goh, Danny Liew, Olga Ischenko, Liubov D. Robman, KhinZaw Aung, Tania Cipriani, Melinda Cain, Andrea J. Richardson, Paul N. Baird, and Robyn Langham
Volume & Issue
Volume 52, Issue 7
Pages
4639-4644

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • Treatment costs for a patient with early-stage glaucoma are about $2,000 less than those of a patient diagnosed with a later stage of the disease.  
  • DR Treatment Savings in the US
    Every year, the U.S. saves an estimated $1.6 billion by treating DR.  
  • Omega-3 polyunsaturated fatty acids have been found to protect against the development and progression of deterioration of the retina (retinopathy).  
  • Of the 8 Million older Americans at high risk of developing advanced age-related macular degeneration (AMD), 1.3 million will develop advanced AMD within 5 years.  However the NEI-sponsored Age-Related Eye…  
  • Macugen to treat wet age-related macular degeneration (AMD)
    A new FDA-approved ophthalmic drug that treats wet age-related macular degeneration (AMD)– pegaptanib sodium (Macugen)– reduced vision loss in 70% of clinical trial patients.